SCHEMBL3017663

SCHEMBL3017663

O=S(=O)(c1cccc(Cl)c1Cl)N1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 2/20 0.47
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RAB9A P51151 1/20 0.39
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 2/20 0.38
CHRM1 P11229 1/20 0.38
POLB P06746 2/20 0.37
HTR6 P50406 1/20 0.36
CHRM4 P08173 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999233 0.95 SMN1; SMN2 (0.45) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3018664 0.92 KMT2A (0.48) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3007745 0.90 TSHR (0.44) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3012178 0.89 LMNA (0.44) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3016580 0.89 KMT2A (0.44) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3015125 0.89 LMNA (0.44) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3005306 0.89 TSHR (0.43) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3018936 0.88 TSHR (0.46) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3020813 0.88 KMT2A (0.46) KMT2ALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL3014026 0.87 TSHR (0.44) KMT2ALMNASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885LMNA 80/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.